ArticleBMC psychiatry2025
General polypharmacy, psychotropic polypharmacy, attitudes of patients on psychotropic deprescribing, and associated factors in adult psychiatric outpatients: a survey study in a comprehensive specialized hospital, northwest Ethiopia.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionExcessive polypharmacy causes different problems, including adverse drug reactions and drug-drug interactions. To address the problems, deprescribing has emerged, focusing on reducing the dose or stopping unnecessary medications.
objectiveThis study aimed to explore the prevalence of psychotropic polypharmacy, general polypharmacy, deprescribing attitudes and associated factors for psychotropic medications in adult patients with mental disorders. MATERIALS AND
methodsA facility-based cross-sectional survey study design was conducted to collect data on 123 patients with mental disorders from April 2022 to August 2024. Revised patients' attitudes towards deprescribing (rPATD), trust in physician score, and orientation memory concentration test were used. Descriptive statistics, one-way analysis of variance, and independent t-tests were used. P-value of 0.05 was a cutoff point to determine significant association.
resultsThe prevalence of general polypharmacy and psychiatric polypharmacy was 17.9% [22] and 29.3% [36] respectively. Near to half of patients (54, 44.7%) felt they were taking large number of medications; more than half (69, 56.1%) felt spending a lot of money. Patients with age of > 60 years had significant differences with patients aged from 18 to 44 (p < 0.001) and 45-59 (p < 0.01) years on burden and appropriateness domains respectively. Patients who took < 5 medications had significant difference (p < 0.001) with patients taking ≥ 5 medications on both burden and appropriateness domains.
conclusionThe findings of the study showed many patients had meaningful prevalence of general polypharmacy and psychotropic polypharmacy. Patients expressed diverse attitudes toward deprescribing, affected by different factors. This study is conducted in a single health facility with small sample size. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.